Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
0.6480
+0.0718 (12.46%)
At close: Nov 17, 2026, 4:00 PM EST
0.6762
+0.0282 (4.35%)
After-hours: Nov 17, 2026, 6:05 PM EST
Tiziana Life Sciences Employees
Tiziana Life Sciences had 10 employees as of December 31, 2025. The number of employees increased by 1 or 11.11% compared to the previous year. That makes Tiziana Life Sciences the 40,397th largest employer in the world and 6,074th in the United States.
Employees
10
Change (1Y)
1
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$2,518,600
Market Cap
82.96M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | 1 | 11.11% |
| Dec 31, 2024 | 9 | 0 | - |
| Dec 31, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 9 | -5 | -35.71% |
| Dec 31, 2021 | 14 | 3 | 27.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Rani Therapeutics Holdings | 71 |
| Milestone Pharmaceuticals | 38 |
| Corbus Pharmaceuticals Holdings | 36 |
| NeurAxis | 24 |
| Nutriband | 13 |
| Atara Biotherapeutics | 10 |
| Coya Therapeutics | 8 |
TLSA News
- 5 days ago - Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London - GlobeNewsWire
- 8 days ago - Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab - GlobeNewsWire
- 8 days ago - Tiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast - GlobeNewsWire
- 12 days ago - Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results - GlobeNewsWire
- 15 days ago - Tiziana's experimental MS treatment meets main goals in mid-stage study - Reuters
- 27 days ago - Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto - GlobeNewsWire
- 4 weeks ago - Tiziana Life Sciences doses last patient in foralumab trial - TheFly
- 4 weeks ago - Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease - GlobeNewsWire